• Product name
  • Description
    Goat polyclonal to IL4R
  • Host species
  • Specificity
    The antibody will neutralize human cell surface IL-4 receptor mediated-bioactivity.
  • Tested applications
    Suitable for: WB, Neutralising, Indirect ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Recombinant human IL-4 sR, expressed in Sf21 insect cells

  • Positive control
    • Recombinant human IL-4
  • General notes
    Endotoxin level is < 10 ng per mg antibody as determined by the LAL method.


  • Form
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
  • Storage buffer
    Preservative: None
    Constituents: PBS
  • Concentration information loading...
  • Purity
    Protein G purified
  • Purification notes
    IgG Fraction of Antiserum purified using protein G chromatography.
  • Clonality
  • Isotype
  • Research areas


Our Abpromise guarantee covers the use of ab50277 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 - 2 µg/ml. Predicted molecular weight: 89 kDa.
Neutralising Use a concentration of 5 - 10 µg/ml.
Indirect ELISA Use a concentration of 0.5 - 1 µg/ml.


  • Function
    Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammmation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.
    Soluble IL4R (sIL4R) inhibits IL4-mediated cell proliferation and IL5 up-regulation by T-cells.
  • Tissue specificity
    Isoform 1 and isoform 2 are highly expressed in activated T-cells.
  • Sequence similarities
    Belongs to the type I cytokine receptor family. Type 4 subfamily.
    Contains 1 fibronectin type-III domain.
  • Domain
    The extracellular domain represents the IL4 binding protein (IL4BP).
    The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
    The box 1 motif is required for JAK interaction and/or activation.
    Contains 1 copy of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in modulation of cellular responses. The phosphorylated ITIM motif can bind the SH2 domain of several SH2-containing phosphatases.
  • Post-translational
    On IL4 binding, phosphorylated on C-terminal tyrosine residues. Phosphorylation on any one of tyrosine residues, Tyr-575, Tyr-603 or Tyr-631, is required for STAT6-induced gene induction.
    The soluble form (sIL4R/IL4BP) can also be produced by proteolytic cleavage at the cell surface (shedding) by a metalloproteinase.
  • Cellular localization
    Secreted and Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD124 antibody
    • IL 4R alpha antibody
    • IL-4 receptor subunit alpha antibody
    • IL-4-binding protein antibody
    • IL-4R subunit alpha antibody
    • IL-4R-alpha antibody
    • IL-4RA antibody
    • IL4-BP antibody
    • Il4r antibody
    • IL4R nirs variant 1 antibody
    • IL4RA antibody
    • IL4RA_HUMAN antibody
    • Interleukin 4 receptor alpha chain antibody
    • Interleukin 4 receptor antibody
    • sIL4Ralpha/prot antibody
    • Soluble IL-4 receptor subunit alpha antibody
    • Soluble IL-4R-alpha antibody
    • Soluble interleukin-4 receptor subunit alpha antibody
    see all


This product has been referenced in:
  • Liu H  et al. Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells. Oncotarget 8:38113-38135 (2017). Read more (PubMed: 28498822) »
  • Jiang J  et al. Activation of spinal neuregulin 1-ErbB2 signaling pathway in a rat model of cancer-induced bone pain. Int J Oncol 45:235-44 (2014). Read more (PubMed: 24818668) »

See all 2 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab50277.
Please use the links above to contact us or submit feedback about this product.


Sign up